GuidelineRespiration; international review of thoracic diseases2021
Swiss Recommendations for the Follow-Up and Treatment of Pulmonary Long COVID.
Guideline in Respiration; international review of thoracic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Sequelae of COVID-19 among previously hospitalized patients up to 1 year after discharge: a systematic review and meta-analysis.Infection · 2022Pooled it
- High-doseThe European respiratory journal · 2022Trial
- Management of long COVID-19 in children and adolescents: from diagnosis to therapeutically approaches.Annals of medicine · 2026Review
- Interpretable machine learning for predicting low-dose methylprednisolone effectiveness in long COVID.iScience · 2026Article
- Clinical Manifestations of Subjects with Long COVID and Their Associations with Drug Use: The BioICOPER Study.Biomedicines · 2026Article
- A Retrospective Observational Study of Pulmonary Impairments in Long COVID Patients.Biomedicines · 2026Article
- Assessment and management of post-COVID-19 pulmonary complications: a rapid review.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Interest of ventilation/perfusion SPECT/CT in patients with post-COVID condition: a multicenter observational study.European journal of nuclear medicine and molecular imaging · 2025Observational
- Physiotherapy interventions in post- and long-COVID-19: a scoping review of the literature up to February 2023.BMC health services research · 2025Article
- Individually Tailored Physiotherapy in Persons With Respiratory Symptoms Related to Post-Acute Sequelae of COVID-19: A Feasibility Study With Mixed Methods.Health science reports · 2025Article
- Article
- Review
- The clinical, functional, and radiological effect of long-term used immunosuppressive therapy for post-COVID-19 interstitial lung disease.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2023Article
- Circulating calprotectin levels four months after severe and non-severe COVID-19.BMC infectious diseases · 2023Observational
- Post-hospitalization rehabilitation alleviates long-term immune repertoire alteration in COVID-19 convalescent patients.Cell proliferation · 2023Article
- Risk factors for the development of interstitial lung disease following severe COVID-19 pneumonia and outcomes of systemic corticosteroid therapy: 3-month follow-up.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2023Article
- Implications of the COVID-19 pandemic on athletes, sports events, and mass gathering events: Review and recommendations.Sports medicine and health science · 2023Review
- Post-COVID Interstitial Lung Disease and Other Lung Sequelae.Clinics in chest medicine · 2023Review
- Review
- Pulmonary Recovery 12 Months after Non-Severe and Severe COVID-19: The Prospective Swiss COVID-19 Lung Study.Respiration; international review of thoracic diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEmerging evidence suggests that long-term pulmonary symptoms and functional impairment occurs in a proportion of individuals following SARS-CoV-2 infection. Although the proportion of affected patients remains to be determined, physicians are increasingly being confronted with patients reporting respiratory symptoms and impairment beyond the acute phase of COVID-19. In face of limited evidence, the Swiss Society for Pulmonology established a working group to address this area of unmet need and formulated diagnostic and treatment recommendations for the care of patients with pulmonary long COVID (LC).
methodThe Swiss COVID Lung Study group and Swiss Society for Pulmonology (SSP) formulated 13 questions addressing the diagnosis and treatment of pulmonary LC. A survey within the SSP special interest groups involved in care of LC patients was conducted in Switzerland. A CORE process/Delphi-like process was used to formulate recommendations. Forty experienced pulmonologists replied to the first survey and 22 completed the second follow-up survey. Agreement of ≥70% consensus led to formulation of a recommendation.
resultsThe participants in the survey reached consensus and formulated a strong recommendation for regarding the following points. Patients hospitalized for COVID-19 should have a pulmonary assessment including pulmonary function tests. Symptomatic subjects affected by COVID-19, including those with mild disease, should benefit from a pulmonary follow-up. Persistent respiratory symptoms after COVID-19 should be investigated by a pulmonary follow-up including plethysmography, diffusion capacity measurement, and blood gases analysis. Individuals having suffered from COVID-19 and who present with persistent respiratory symptoms should be offered a rehabilitation. Additional questions were given moderateor weak recommendations for. The panel did not reach sufficient consensus for pharmacological therapy (e.g., therapy specifically targeting lung fibrosis) to formulate recommendations for LC drug treatment.
conclusionThe formulated recommendations should serve as an interim guidance to facilitate diagnosis and treatment of patients with pulmonary LC. As new evidence emerges, these recommendations may need to be adapted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.